Core Viewpoint - The company anticipates significant financial improvement for the six months ending June 30, 2025, with a projected comprehensive income of at least RMB 500 million, marking an increase of at least 387% compared to RMB 103 million for the same period in 2024 [1][2] Financial Performance Expectations - The company expects to turn a loss into profit, with a projected net profit of at least RMB 50 million for the six months ending June 30, 2025, compared to a net loss of RMB 1.238 billion for the same period in 2024 [1] - The adjusted net loss (non-IFRS) for the six months ending June 30, 2024, was RMB 251 million, which is expected to turn into an adjusted net profit (non-IFRS) of at least RMB 120 million for the 2025 mid-term period [1] Revenue Growth Drivers - The anticipated financial improvement is primarily attributed to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and comprehensive "AI + Robotics" technology [2] - The company received an upfront payment of USD 51 million, which has been recognized as revenue for the six months ending June 30, 2025, significantly contributing to the expected revenue growth [2] - Further payments are expected under the agreement with DoveTree, which will be recognized as revenue in future installments [2]
晶泰控股(02228.HK)盈喜：预计中期经调整纯利不少于1.2亿元